Format

Send to

Choose Destination
Nature. 2018 May;557(7704):228-232. doi: 10.1038/s41586-018-0056-8. Epub 2018 Apr 23.

Nanoscale synthesis and affinity ranking.

Author information

1
Department of Discovery Chemistry, Merck & Co., Inc., Boston, MA, USA.
2
Research and Development, AbbVie, North Chicago, IL, USA.
3
Department of Pharmacology, Merck & Co., Inc., Boston, MA, USA.
4
Department of Discovery Chemistry, Merck & Co., Inc., Boston, MA, USA. tcernak@umich.edu.
5
Department of Medicinal Chemistry, Department of Chemistry, Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA. tcernak@umich.edu.

Abstract

Most drugs are developed through iterative rounds of chemical synthesis and biochemical testing to optimize the affinity of a particular compound for a protein target of therapeutic interest. This process is challenging because candidate molecules must be selected from a chemical space of more than 1060 drug-like possibilities 1 , and a single reaction used to synthesize each molecule has more than 107 plausible permutations of catalysts, ligands, additives and other parameters 2 . The merger of a method for high-throughput chemical synthesis with a biochemical assay would facilitate the exploration of this enormous search space and streamline the hunt for new drugs and chemical probes. Miniaturized high-throughput chemical synthesis3-7 has enabled rapid evaluation of reaction space, but so far the merger of such syntheses with bioassays has been achieved with only low-density reaction arrays, which analyse only a handful of analogues prepared under a single reaction condition8-13. High-density chemical synthesis approaches that have been coupled to bioassays, including on-bead 14 , on-surface 15 , on-DNA 16 and mass-encoding technologies 17 , greatly reduce material requirements, but they require the covalent linkage of substrates to a potentially reactive support, must be performed under high dilution and must operate in a mixture format. These reaction attributes limit the application of transition-metal catalysts, which are easily poisoned by the many functional groups present in a complex mixture, and of transformations for which the kinetics require a high concentration of reactant. Here we couple high-throughput nanomole-scale synthesis with a label-free affinity-selection mass spectrometry bioassay. Each reaction is performed at a 0.1-molar concentration in a discrete well to enable transition-metal catalysis while consuming less than 0.05 milligrams of substrate per reaction. The affinity-selection mass spectrometry bioassay is then used to rank the affinity of the reaction products to target proteins, removing the need for time-intensive reaction purification. This method enables the primary synthesis and testing steps that are critical to the invention of protein inhibitors to be performed rapidly and with minimal consumption of starting materials.

PMID:
29686415
DOI:
10.1038/s41586-018-0056-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center